Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia
Open Access
- 13 February 2021
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 96 (5), E154-E157
- https://doi.org/10.1002/ajh.26122
Abstract
No abstract availableFunding Information
- NIH Clinical Center (R01CA235622)
This publication has 7 references indexed in Scilit:
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialThe Lancet Haematology, 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaThe New England Journal of Medicine, 2020
- Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).Journal of Clinical Oncology, 2020
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AMLBlood, 2020
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaBlood, 2020
- Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).Journal of Clinical Oncology, 2019
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood, 2017